Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer
10.1097/CM9.0000000000003094
- VernacularTitle:Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer
- Author:
Tao JIANG
1
,
2
;
Jian CHEN
;
Haowei WANG
;
Fengying WU
;
Xiaoxia CHEN
;
Chunxia SU
;
Haiping ZHANG
;
Fei ZHOU
;
Ying YANG
;
Jiao ZHANG
;
Huaibo SUN
;
Henghui ZHANG
;
Caicun ZHOU
;
Shengxiang REN
Author Information
1. Department of Medical Oncology, Shanghai Pulmonary Hospital &
2. Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China
- Keywords:
Non-small-cell lung cancer (NSCLC);
Programmed death 1 (PD-1) blockade;
Gene panel;
Prediction;
Biomarker
- From:
Chinese Medical Journal
2024;137(18):2213-2222
- CountryChina
- Language:Chinese
-
Abstract:
Background::Programmed death 1 (PD-1) blockade plus chemotherapy has become the new first-line standard of care for patients with advanced non-small-cell lung cancer (NSCLC). Yet not all NSCLC patients benefit from this regimen. This study aimed to investigate the predictors of PD-1 blockade plus chemotherapy in untreated advanced NSCLC.Methods::We integrated clinical, genomic, and survival data from 287 patients with untreated advanced NSCLC who were enrolled in one of five registered phase 3 trials and received PD-1 blockade plus chemotherapy or chemotherapy alone. We randomly assigned these patients into a discovery cohort ( n = 125), a validation cohort ( n = 82), and a control cohort ( n = 80). The candidate genes that could predict the response to PD-1 blockade plus chemotherapy were identified using data from the discovery cohort and their predictive values were then evaluated in the three cohorts. Immune deconvolution was conducted using transcriptome data of 1014 NSCLC patients from The Cancer Genome Atlas dataset. Results::A genomic variation signature, in which one or more of the 15 candidate genes were altered, was correlated with significantly inferior response rates and survival outcomes in patients treated with first-line PD-1 blockade plus chemotherapy in both discovery and validation cohorts. Its predictive value held in multivariate analyses when adjusted for baseline parameters, programmed cell death ligand 1 (PD-L1) expression level, and tumor mutation burden. Moreover, applying both the 15-gene panel and PD-L1 expression level produced better performance than either alone in predicting benefit from this treatment combination. Immune landscape analyses revealed that tumors with one or more variation in the 15-gene panel were associated with few immune infiltrates, indicating an immune-desert tumor microenvironment.Conclusion::These findings indicate that a 15-gene panel can serve as a negative prediction biomarker for first-line PD-1 blockade plus chemotherapy in patients with advanced NSCLC.
